Literature DB >> 23190331

EPS-I polysaccharide protects Mycoplasma pulmonis from phagocytosis.

Brandon M Shaw1, James M Daubenspeck, Warren L Simmons, Kevin Dybvig.   

Abstract

Few mycoplasmal polysaccharides have been described and little is known about their role in pathogenesis. The infection of mice with Mycoplasma pulmonis has been utilized in many in vivo and in vitro studies to gain a better understanding of host-pathogen interactions during chronic respiratory infection. Although alveolar macrophages have a primary role in host defence, M. pulmonis is killed inefficiently in vitro. One antiphagocytic factor produced by the mycoplasma is the family of phase- and size-variable Vsa lipoproteins. However, bacteria generally employ multiple strategies for combating host defences, with capsular polysaccharide often having a key role. We show here that mutants lacking the EPS-I polysaccharide of M. pulmonis exhibit increased susceptibility to binding and subsequent killing by alveolar macrophages. These results give further insight into how mycoplasmas are able to avoid the host immune system and sustain a chronic infection.
© 2012 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190331      PMCID: PMC3535568          DOI: 10.1111/1574-6968.12048

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  33 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

Review 2.  Phagocytosis of microbes: complexity in action.

Authors:  David M Underhill; Adrian Ozinsky
Journal:  Annu Rev Immunol       Date:  2001-12-07       Impact factor: 28.527

3.  Microarray analysis of transposition targets in Escherichia coli: the impact of transcription.

Authors:  Dipankar Manna; Adam M Breier; N Patrick Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

4.  Identification and serological specificity of a polysaccharide component from Mycoplasma bovis.

Authors:  B W Brooks; C L Lutze-Wallace; P Lu; R H Robertson
Journal:  Vet Res Commun       Date:  2004-04       Impact factor: 2.459

5.  Segregation of the Escherichia coli chromosome terminus.

Authors:  Yongfang Li; Brenda Youngren; Kirill Sergueev; Stuart Austin
Journal:  Mol Microbiol       Date:  2003-11       Impact factor: 3.501

6.  Mycoplasma pneumoniae induces airway epithelial cell expression of MUC5AC in asthma.

Authors:  M Kraft; K B Adler; J L Ingram; A L Crews; T P Atkinson; C B Cairns; D C Krause; H W Chu
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

Review 7.  What does mucin have to do with lung disease?

Authors:  Judith A Voynow
Journal:  Paediatr Respir Rev       Date:  2002-06       Impact factor: 2.726

8.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  The genome sequence of Mycoplasma mycoides subsp. mycoides SC type strain PG1T, the causative agent of contagious bovine pleuropneumonia (CBPP).

Authors:  Joakim Westberg; Anja Persson; Anders Holmberg; Alexander Goesmann; Joakim Lundeberg; Karl-Erik Johansson; Bertil Pettersson; Mathias Uhlén
Journal:  Genome Res       Date:  2004-02       Impact factor: 9.043

10.  C-Mannosylation of MUC5AC and MUC5B Cys subdomains.

Authors:  Juan Perez-Vilar; Scott H Randell; Richard C Boucher
Journal:  Glycobiology       Date:  2004-01-12       Impact factor: 4.313

View more
  8 in total

1.  Highly dynamic genomic loci drive the synthesis of two types of capsular or secreted polysaccharides within the Mycoplasma mycoides cluster.

Authors:  Clothilde Bertin; Corinne Pau-Roblot; Josiane Courtois; Lucía Manso-Silván; Florence Tardy; François Poumarat; Christine Citti; Pascal Sirand-Pugnet; Patrice Gaurivaud; François Thiaucourt
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

2.  O-linked protein glycosylation in Mycoplasma.

Authors:  David S Jordan; James M Daubenspeck; Audra H Laube; Matthew B Renfrow; Kevin Dybvig
Journal:  Mol Microbiol       Date:  2013-10-18       Impact factor: 3.501

3.  Rhamnose biosynthesis in mycoplasmas requires precursor glycans larger than monosaccharide.

Authors:  David S Jordan; James M Daubenspeck; Kevin Dybvig
Journal:  Mol Microbiol       Date:  2013-07-19       Impact factor: 3.501

Review 4.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

5.  Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei.

Authors:  Michael J Dillon; Rachael A Loban; Dana E Reed; Peter Thorkildson; Kathryn J Pflughoeft; Sujata G Pandit; Paul J Brett; Mary N Burtnick; David P AuCoin
Journal:  Virulence       Date:  2016-04-20       Impact factor: 5.882

6.  Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens.

Authors:  Nicholas J Harmer; Richard Chahwan
Journal:  Virulence       Date:  2016-05-25       Impact factor: 5.882

Review 7.  Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors.

Authors:  Chen Yiwen; Wu Yueyue; Qin Lianmei; Zhu Cuiming; You Xiaoxing
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 8.  The Mycoplasma spp. 'Releasome': A New Concept for a Long-Known Phenomenon.

Authors:  Patrice Gaurivaud; Florence Tardy
Journal:  Front Microbiol       Date:  2022-04-15       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.